A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive Breast Cancer
Interventions: DRUG: AZD2014|DRUG: Everolimus|DRUG: Fulvestrant
Sponsor: Queen Mary University of London
Collaborators: AstraZeneca